Workflow
网传“可复美未检测到重组胶原蛋白”,巨子生物:坚决否认,会尽快启动法律程序

Core Viewpoint - The company firmly denies allegations regarding the absence of recombinant collagen in its products and plans to initiate legal action against the spreaders of false information [1][3]. Group 1: Company Response - The company issued a statement refuting claims of serious fraud and emphasized adherence to research ethics and industry responsibilities, ensuring compliance with relevant regulations [1]. - All products undergo a three-tier verification system, including raw material checks, production quality control, and finished product testing, to guarantee safety and reliability [1]. - The company has conducted multiple tests on its products, confirming that collagen content exceeds 0.1%, contradicting the alleged figure of 0.0177% [1][2]. Group 2: Third-Party Testing - To address consumer concerns, the company has engaged several authoritative third-party testing organizations to conduct further tests, with results to be published promptly [2]. - The testing methods referenced are based on the national pharmaceutical industry standard YY/T 1947-2025, as there are currently no industry or national standards for collagen content in cosmetics [2]. Group 3: Allegations and Legal Action - The company criticized the testing methods used in the allegations, stating they lack rigorous methodological validation and thus yield unreliable results [3]. - The company has gathered evidence against the malicious spread of false claims and will pursue legal action to protect its rights and the interests of consumers and investors [3]. - The company expressed its desire to focus on industry growth rather than engaging in a cycle of self-defense against organized smear campaigns [3].